PCSK9 Inhibitors, Including Inclisiran, Show Sustained and Significant Lipid Reduction in Familial Hypercholesterolemia

A comprehensive new systematic review and meta-analysis published in Open Heart has affirmed the strong and sustained efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) targeting therapies—especially the small-interfering RNA (siRNA) agent inclisiran (Leqvio; Novartis)—in managing familial hypercholesterolemia (FH). FH is a genetic disorder causing extremely high levels of low-density lipoprotein cholesterol (LDL-C), which significantly increases the risk of premature atherosclerotic cardiovascular disease.

The meta-analysis, which included 23 randomized controlled trials (RCTs) with a total of 4,282 FH patients, found that PCSK9-targeting therapies offer substantial reductions across a panel of harmful lipid biomarkers.

Key Findings on Efficacy

PCSK9-targeting therapies, which include monoclonal antibodies (like evolocumab and alirocumab) and siRNA agents (like inclisiran), work by increasing the number of LDL receptors on liver cells, thereby boosting the liver’s ability to clear “bad” cholesterol from the bloodstream.

Compared to placebo, the therapies demonstrated statistically significant and clinically relevant mean reductions:

LDL-C (Low-Density Lipoprotein Cholesterol): –46.64%
ApoB (Apoprotein B): –34.94%
Lp(a) (Lipoprotein A): –22.70%
TGL (Triglyceride Levels): –15.18%

Impact Across FH Subtypes and Age Groups

The study provided crucial data on the differentiation between FH subtypes:

Heterozygous FH (HeFH) vs. Homozygous FH (HoFH): Patients with the more common HeFH (inherited from one parent) showed significantly greater responses to PCSK9 therapy in reducing LDL-C, ApoB, and TGL compared to those with the rarer, more severe HoFH (inherited from both parents). This highlights the need for subtype distinction in clinical decision-making.
Pediatric Patients: Young patients also experienced substantial reductions in key biomarkers: LDL-C (–38.15%), ApoB (–33.66%), and Lp(a) (–17.1%).

Safety Profile

The meta-analysis concluded that these therapies possess a favorable safety profile:

While injection site adverse effects were significantly more common with PCSK9 therapies compared to placebo, there was no significant difference in the rate of serious adverse effects or adverse effects leading to treatment discontinuation.

“These therapies have a favorable safety profile, with minimal significant adverse events reported, making them a well-tolerated and promising treatment option for patients with persistently high LDL-C levels despite standard lipid-lowering therapies,” the authors concluded.

The findings strongly support the broader use of this novel class of cholesterol-lowering agents, particularly inclisiran with its convenient biannual dosing, as an effective and sustained treatment option for FH patients who struggle to reach cholesterol targets with conventional methods like statins and ezetimibe.